# Progress Note 05 — Preventive Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Barbara Jordan (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML030-SYN
- Date: 2026-08-17
- Fictional facility: St. Posthumous Health Center
- Fictional author: Evangeline Moss, MD
- Calendar frame: modern shifted

- Visit type: Preventive Visit
- Services: CPT 99396 (periodic preventive medicine, established patient, age 40 to 64) with CPT 99497 (advance care planning), both on the same day

## Chief complaint

Periodic adult preventive visit. **S**

## History of present illness

Ms. Jordan is a 44-year-old professor with active primary progressive multiple sclerosis who comes for her yearly preventive visit seven weeks after her four-month review. She had her two ocrelizumab half-doses three months ago and has had no infections since. Her walking is unchanged: she uses her cane on campus and a rollator at home for longer distances. The summer heat makes her legs heavier by the afternoon; her cooling vest and moving her seminars to the morning have helped. She has had no falls; on one hot afternoon in July her legs gave way briefly at home and her rollator caught her. Her bladder is better on mirabegron. She is preparing for the autumn term and several speaking engagements, and her university has put the accommodations she asked for in place. She had her bone density scan this morning. **S**

| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 44 |
| Multiple sclerosis | Ocrelizumab started three months ago; walking unchanged; no relapse |
| Heat | Legs heavier in the afternoon heat; cooling vest helps |
| Mood | PHQ-2 0 |

## Health risk assessment

Completed by the patient on the clinic's online form before the visit and reviewed with her by Dr. Moss. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Good |
| Psychosocial | Engaged in her teaching and public work; good supports of her choosing; low stress apart from the term's start |
| Substance use | No tobacco; occasional alcohol within low-risk limits; no drug use |
| Physical activity | Home exercise program from physical therapy most days; pool exercise twice a week in cool water |
| Nutrition | Regular meals; dairy at most meals for calcium; takes vitamin D3 |
| Sleep | Seven hours; up once a night at most |
| Falls and home safety | No falls this year; one near-fall in the July heat; grab bars and a shower seat installed; no loose rugs |
| Driving | Drives safely by her account; no hand-control need at present |
| Work | Accessible room, chair and lectern, and reserved parking in place |
| Activities of daily living | Independent; tires by late afternoon |
| Seat belt and smoke alarms | Always wears a seat belt; smoke alarms tested |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Fatigue by late afternoon, worse in the heat; no fever or weight change |
| Eyes | Negative | No blurred or double vision |
| Ears, nose, mouth, and throat | Negative | No hearing change or sore mouth |
| Cardiovascular | Negative | No chest pain or leg swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | Regular bowels; no diarrhea |
| Genitourinary | Negative | Urgency improved; up once a night at most; no burning |
| Breast | Negative | No lump or nipple change |
| Musculoskeletal | Positive | Leg stiffness in the mornings, eased by stretching |
| Integumentary | Negative | No rash or cold sores |
| Neurological | Positive | Legs heavier in the heat, settling when she cools down; no new numbness or weakness lasting more than a day |
| Psychiatric | Negative | Mood steady; PHQ-2 0 |

12 systems reviewed. **S**

## Current medications

- Cholecalciferol (vitamin D3) 2000 units (50 mcg) oral capsule, one capsule daily **S**
- Baclofen 10 mg oral tablet, one tablet three times a day **S**
- Mirabegron 25 mg extended-release oral tablet, one tablet daily **S**
- Ocrelizumab 300 mg intravenous infusion on day 1 and day 15, then 600 mg every 6 months, after methylprednisolone 100 mg intravenously, an antihistamine and acetaminophen, in the infusion center **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/74 mmHg; pulse 74 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 83.4 kg; BMI 27.9 kg/m². All vital signs are synthetic.

Hemoglobin A1c: 5.4%; Total cholesterol: 186 mg/dL; LDL cholesterol: 110 mg/dL; HDL cholesterol: 56 mg/dL; Triglycerides: 98 mg/dL; PHQ-2: 0. All results are synthetic.

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Well; weight 83.4 kg; blood pressure 118/74 |
| Eyes | Pupils equal and reactive; no nystagmus |
| Neck | No thyroid enlargement or lymph nodes |
| Breasts | Clinical breast examination with a chaperone, at her choice: no masses, skin or nipple changes, or axillary nodes |
| Cardiovascular | Regular rhythm; no murmur; no leg swelling |
| Respiratory | Clear |
| Abdomen | Soft, non-tender |
| Skin | No rash or suspicious lesions |
| Neurological | Spastic gait with the cane, as before; modified Ashworth 1+ in both legs; strength 4 out of 5 in the hip flexors; brisk leg reflexes |
| Psychiatric | Engaged and precise |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Periodic adult preventive visit completed**. Health risk assessment reviewed and the prevention plan updated. Mammogram ordered: screening every two years from 40 is recommended, and the ocrelizumab label advises standard breast cancer screening. Cervical screening with HPV testing done today. Bone density today: lumbar spine and hip Z-scores -0.4 and -0.6, within the expected range for age. A1c 5.4%; LDL 110 mg/dL with a low ten-year risk. **S**
   - Mammogram this month.
   - Influenza and COVID-19 vaccines at the October review, at least two weeks before her next infusion.
   - Colorectal cancer screening from 45.
   - Next preventive visit in one year.
2. **Active primary progressive multiple sclerosis** (G35.B1). Stable on ocrelizumab; heat brings temporary heaviness in her legs that settles with cooling, which is pseudo-relapse, not new disease activity. She chose to complete advance care planning today. **S**
   - Continue cooling measures and morning teaching.
   - Re-baseline brain MRI before the October review.
3. **Vitamin D deficiency** (E55.9). Replete on vitamin D3; bone density normal for age. **S**
   - Continue vitamin D3 2000 units daily and calcium from food.
   - Repeat bone density only if steroid courses accumulate, a fracture occurs, or at menopause.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 118/74 mmHg |
| Depression screening | Completed today | PHQ-2 score 0; PHQ-9 3 seven weeks ago |
| Unhealthy alcohol use screening | Completed today | Occasional use within low-risk limits |
| Tobacco use | Completed today | Never |
| Breast cancer screening | Ordered | Mammogram every two years from 40; no previous mammogram on file; ordered today, with the ocrelizumab label's advice to follow standard screening |
| Cervical cancer screening | Completed today | Primary HPV test with a chaperone present, after she was told each step and agreed; result by phone |
| Colorectal cancer screening | Not indicated | Begins at 45, next year; she prefers a stool test |
| Diabetes and lipid screening | Completed today | A1c 5.4%; total cholesterol 186, LDL 110, HDL 56, triglycerides 98 mg/dL; ten-year risk low, no statin |
| HIV and hepatitis C screening | Up to date | Both negative at intake |
| Bone density | Completed today | Z-scores -0.4 at the spine and -0.6 at the hip; done for reduced mobility and earlier steroid courses |
| Pneumococcal, zoster, Tdap and hepatitis B vaccines | Up to date | PCV20, both recombinant zoster doses, Tdap and both hepatitis B doses given before ocrelizumab |
| Influenza and COVID-19 vaccines, this season | Due | At the October review, at least two weeks before the next infusion |
| Live vaccines | Not indicated | Not recommended on ocrelizumab; varicella and measles immunity documented before treatment |
| Dental and eye examinations | Due | Dental review and an eye examination advised this year |

## Advance care planning

Voluntary advance care planning discussion of about 20 minutes, with her consent. She wants full treatment for any illness that could be reversed, wants to be told plainly what is happening, and wants to make her own decisions. She named a health care agent, recorded in the confidential part of the chart and not named here, and asked that information about her health be shared only with the people she names. She chose not to record other treatment preferences today. To be revisited yearly or after any serious illness. **S**

## Guideline basis

- OCREVUS (ocrelizumab) injection, prescribing information (2026), U.S. National Library of Medicine, DailyMed (Genentech label)
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force
- Breast Cancer: Screening (2024), U.S. Preventive Services Task Force
- Cervical Cancer: Screening (2018), U.S. Preventive Services Task Force

## Follow-up

- Mammogram this month; HPV result by phone. Re-baseline brain MRI and the eight-month review in October, with influenza and COVID-19 vaccines. Next preventive visit in one year. **S**
- Next scheduled visit 2026-10-26: eight-month review before the first full ocrelizumab dose: re-baseline brain MRI, blood counts and immunoglobulins, seasonal vaccines, mobility and work. **S**
